Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...
Viridian Therapeutics (VRDN) reported phase 1 results of VRDN-003 that confirmed its preclinical profile and that met or exceeded expectations.The subcutaneously administered candidate was safe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback